Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33096
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDe Kretser D.M.en
dc.contributor.authorRobertson D.M.en
dc.contributor.authorFrydenberg M.en
dc.contributor.authorBalourdos G.en
dc.contributor.authorStanton P.G.en
dc.contributor.authorO'Donnell L.en
dc.contributor.authorMcLachlan R.I.en
dc.date.accessioned2021-05-14T11:13:22Zen
dc.date.available2021-05-14T11:13:22Zen
dc.date.copyright2002en
dc.date.created20020304en
dc.date.issued2012-10-18en
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism. 87 (2) (pp 546-556), 2002. Date of Publication: 2002.en
dc.identifier.issn0021-972Xen
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/33096en
dc.description.abstractTestosterone (T) treatment suppresses gonadotropin levels and sperm counts in normal men, but the addition of a progestin may improve the efficacy of hormonal contraception. This study aimed to investigate the speed and extent of suppression of testicular germ cell number induced by T plus or minus progestin treatment and correlate these changes with serum gonadotropins and inhibin B levels, testicular androgens, and sperm output. Thirty normal fertile men (31-46 yr) received either testosterone enanthate (TE, 200 mg im weekly) alone or TE plus depot medroxyprogesterone acetate (DMPA, 300 mg im once) for 2, 6, or 12 wk (n = 5 per group) before vasectomy and testis biopsy. Five men (controls) proceeded directly to surgery. The inclusion of DMPA led to a more rapid fall in serum FSH/LH levels (time to 10% baseline: FSH; 12.6 +/- 2.6 vs. 7.9 +/- 1.4 d; LH, 9.9 +/- 3.4 vs. 3.4 +/- 1.7 d, TE vs. TE+DMPA, respectively, mean +/- SD, both P < 0.0001), yet the mean time to reach a sperm count 10% of baseline was not different (23.7 +/- 7.3 vs. 25.3 +/- 13.9 d, NS). The maximum extent of FSH/LH suppression was identical at 12 wk (mean serum FSH 1.2 and 1.6%, and mean LH 0.3 and 0.2% of baseline: TE vs. TE+ DMPA, respectively) as was sperm count suppression (5 of 5 and 4 of 5 men, respectively, with sperm counts <=0.1 x 106/ml). Serum inhibin decreased to 55% control at 12 wk in the TE+DMPA group (P < 0.05) but was unchanged by TE treatment (86% control, NS). Testicular T levels declined to approximately 2% of control levels, but testicular dihydrotestosterone and 5alpha-androstane-3alpha, 17beta-diol (Adiol) levels were not different to control. Germ cell numbers as determined by stereological methods did not differ between TE and TE+DMPA except at 2 wk when type B spermatogonia and early spermatocytes were significantly lower in the TE+DMPA group (P < 0.05). In all groups, a marked inhibition of Apale->B spermatogonial maturation was seen along with a striking inhibition of spermiation. We conclude that: 1) the addition of DMPA hastens the onset of FSH/LH suppression, correlating with a more rapid impairment of spermatogonial development, but in the longer term, neither germ cell number nor sperm count differed; 2) testicular dihydrotestosterone and Adiol levels are maintained during FSH/LH suppression despite markedly reduced T levels suggesting up-regulation of testicular 5alpha-reductase activity; and 3) spermatogonial inhibition is a consistent feature, but spermiation inhibition is also striking and is an important determinant of sperm output.en
dc.languageEnglishen
dc.languageenen
dc.publisherEndocrine Society (8401 Connecticut Ave. Suite 900, Chevy Chase MD 20815, United States)en
dc.titleEffects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1210/jcem.87.2.8231en
dc.publisher.placeUnited Statesen
dc.identifier.pubmedid11836283 [http://www.ncbi.nlm.nih.gov/pubmed/?term=11836283]en
dc.identifier.source34158217en
dc.identifier.institution(McLachlan, O'Donnell, Frydenberg, Robertson) Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Vic. 3168, Australia (Stanton) Institute of Reproduction and Development, Monash University, Clayton, Vic. 3168, Australia (Balourdos, De Kretser) Department of Urology, Monash University, Clayton, Vic. 3168, Australia (McLachlan) Prince Henry's Institute of Medical Research, P.O. Box 5152, Clayton, Vic. 3168, Australiaen
dc.description.addressR.I. McLachlan, Prince Henry's Inst. of Med. Res., P.O. Box 5152, Clayton, Vic. 3168, Australia. E-mail: rob.mclachlan@med.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailMcLachlan R.I.; rob.mclachlan@med.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.deptUrology-
Appears in Collections:Articles
Show simple item record

Page view(s)

12
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.